442 related articles for article (PubMed ID: 28528450)
1. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
Ahlin C; Lundgren C; Embretsén-Varro E; Jirström K; Blomqvist C; Fjällskog M-
Breast Cancer Res Treat; 2017 Aug; 164(3):667-678. PubMed ID: 28528450
[TBL] [Abstract][Full Text] [Related]
2. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
Mrhalová M; Kodet R; Strnad P
Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
[TBL] [Abstract][Full Text] [Related]
3. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.
Ortiz AB; Garcia D; Vicente Y; Palka M; Bellas C; Martin P
PLoS One; 2017; 12(11):e0188068. PubMed ID: 29140993
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.
Reis-Filho JS; Savage K; Lambros MB; James M; Steele D; Jones RL; Dowsett M
Mod Pathol; 2006 Jul; 19(7):999-1009. PubMed ID: 16648863
[TBL] [Abstract][Full Text] [Related]
6. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
7. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
[TBL] [Abstract][Full Text] [Related]
8. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.
Elsheikh S; Green AR; Aleskandarany MA; Grainge M; Paish CE; Lambros MB; Reis-Filho JS; Ellis IO
Breast Cancer Res Treat; 2008 May; 109(2):325-35. PubMed ID: 17653856
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters.
Ravikumar G; Ananthamurthy A
J Cancer Res Ther; 2014; 10(3):671-5. PubMed ID: 25313758
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
13. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
Jirström K; Stendahl M; Rydén L; Kronblad A; Bendahl PO; Stål O; Landberg G
Cancer Res; 2005 Sep; 65(17):8009-16. PubMed ID: 16140974
[TBL] [Abstract][Full Text] [Related]
14. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis.
Xu XL; Chen SZ; Chen W; Zheng WH; Xia XH; Yang HJ; Li B; Mao WM
Breast Cancer Res Treat; 2013 Jun; 139(2):329-39. PubMed ID: 23670132
[TBL] [Abstract][Full Text] [Related]
15. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
[TBL] [Abstract][Full Text] [Related]
16. Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer.
Kronblad A; Helczynska K; Nielsen NH; Påhlman E; Emdin S; Påhlman S; Landberg G
In Vivo; 2003; 17(4):311-8. PubMed ID: 12929585
[TBL] [Abstract][Full Text] [Related]
17. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
18. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
Lundberg A; Lindström LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Breast Cancer Res; 2019 Feb; 21(1):34. PubMed ID: 30819233
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.
Takano Y; Takenaka H; Kato Y; Masuda M; Mikami T; Saegusa M; Okayasu I
J Cancer Res Clin Oncol; 1999; 125(8-9):505-12. PubMed ID: 10480344
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and Predictive Value of
Jeffreys SA; Becker TM; Khan S; Soon P; Neubauer H; de Souza P; Powter B
Front Endocrinol (Lausanne); 2022; 13():895729. PubMed ID: 35784572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
